

Kyowa Hakko Kirin Announces the Establishment of a Regional Headquarters Function for the Asia and Oceania Region in Singapore

Tokyo, Japan — January 29, 2018: Kyowa Hakko Kirin Co., Ltd. (President & CEO: Nobuo Hanai; “Kyowa Hakko Kirin”) today announces that on April 1, 2018, a regional headquarters function for the Asia and Oceania region will be established in Singapore.

The objective of establishing a regional headquarters function for the Asia and Oceania region is to achieve further organic growth of Kyowa Hakko Kirin’s pharmaceutical business in the pharmaceutical market in Asia, which is expected to grow in the future. The company’s current Singapore subsidiary Kyowa Hakko Kirin (Singapore) Pte. Ltd. will become the regional headquarters for the Asia and Oceania region, and with a focus on Kyowa Hakko Kirin’s local companies in Asia (China, South Korea, Taiwan, Hong Kong, Thailand, and Malaysia), the business operations for the overall Asia and Oceania region, excluding Japan, will be managed as a region by the regional headquarters. Specifically, the new headquarters will promote the following three points.

- 1) Based on the pharmaceutical needs in the Asia and Oceania region excluding Japan, formulate and execute a growth strategy and product portfolio strategy that suits the characteristics of the region.
- 2) Be responsible for and manage each business process, including supply chain management (SCM), maintenance of pharmaceutical affairs, quality assurance and safety management, of the products for the Asia and Oceania region excluding Japan, and respond to the regulations in each country and region.
- 3) Without being limited to those countries and regions with an existing local company, expand the sales of Kyowa Hakko Kirin products to other countries and regions in Asia and Oceania (excluding Japan).

“This is a significant milestone for our overseas business,” said Toshifumi Mikayama, Ph.D., Director of the Board, Managing Executive Officer, Director of Overseas Department of Kyowa Hakko Kirin. “We will strive to expand our Asian and Oceanian business through this function in order to contribute the patients and their families in the countries and regions”

In relation to this change, the name of the company’s Overseas Business Department will be changed to the Overseas Business Planning Department as of April 1, 2018, and part of the department’s functions will be successively transferred to the newly established Asia and Oceania regional headquarters function.

The Kyowa Hakko Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies.